Learn more about BARDA’s impact throughout the COVID-19 response
Enhancing the Nation's PUBLIC HEALTH SECURITY and emergency preparedness by facilitating communication on innovative products and solutions between federal agencies and public stakeholders.
22 EUAs for BARDA-supported SARS CoV-2 Diagnostic Tests
Over 94,000 patients transfused with convalescent plasma under BARDA-supported expanded access programs
COVID-19 CoronaWatch requests from every state in the USA
600+ COVID-19 CoronaWatch Virtual Market Research Meetings with innovative companies
115.1M+ Diagnostic Test Kits Shipped by BARDA supported Partners
COVID-19 contract awards in as few
as 9 days
STATEMENT FROM THE BARDA DIRECTOR
on the launch of BARDA’s newest innovation program BARDA Ventures
Dr. Gary Disbrow, BARDA Director
BARDA provides a systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.
ASPR focuses on preparedness planning and response; building federal emergency medical operational capabilities; countermeasures research, and grants to strengthen the capabilities of health care systems to minimize the health impacts of public health emergencies.
NIH is responsible for conducting research to better understand public health threats and establish a foundation for developing medical countermeasures.
FDA's responsibility is to ensure that medical countermeasures (MCMs)-such as drugs, vaccines, and diagnostic tests-to counter these threats are safe, effective, and secure.
The CDC leads the emergency preparedness and response activities by providing strategic coordination for activities across local, state, national, and international public health partners.
The DHS is charged with securing the nation from the many threats we face. These threats include natural and man-made biological, chemical, radiological, and nuclear threats.